プロジェクトアイテム | 適応症 | 研究段階 | 協力のご要請 |
BIA202204 | Sepsis/ HLH/ CRS | Ready for CMC development | License-out or co-development |
製造番号 | 種類 | 製品説明 | 構造 | 純度 | 特徴 |
---|---|---|---|---|---|
CRS-B005 | Human | ClinMax™ Human IL-10 ELISA Kit | |||
IL0-C4248 | Cynomolgus | Cynomolgus IL-10 Protein, His Tag | ![]() |
![]() ![]() |
|
IL0-H5219 | Human | Human IL-10 Protein, premium grade | ![]() |
![]() ![]() |
|
IL0-M4248 | Mouse | Mouse IL-10 Protein, His Tag | ![]() |
![]() ![]() |
|
IL0-H4248 | Human | Human IL-10 Protein, His Tag | ![]() |
![]() ![]() |
Mouse IL-10, His Tag (Cat. No. IL0-M4248) inhibits LPS-induced secretion of IL-6 by RAW264.7 cells. The EC50 for this effect is 0.27-0.39 ng/mL (Routinely tested).
Immobilized Human IL-10, premium grade (Cat. No. IL0-H5219) at 5 μg/mL (100 μL/well) can bind Cynomolgus IL-10 R alpha Protein, Fc Tag (Cat. No. ILR-C5256) with a linear range of 0.1-2 ng/mL (QC tested).
The purity of Human IL-10, premium grade (Cat. No. IL0-H5219) is more than 90% and the molecular weight of this protein is around 32-42 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant anti-InE monoclonal antibody | CmAb-(IL10)2 | Phase 1 Clinical | Dingfu Biotarget Co Ltd | Solid tumours | Details |
WP-1303 (worgpharma) | ATX-MS-1467; ATX-MS-01; M-2736; WP-1303; MSC-2358825A | Phase 2 Clinical | Apitope Technology | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Myeloma | Details |
KLS-2031 | KLS-2031 | Phase 2 Clinical | Kolon Life Science. Inc | Radiculopathy | Details |
This web search service is supported by Google Inc.